Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Analyst thinks sales of Arena's lorcaserin will trail other obesity drugs, downgrades stock
Analyst thinks sales of Arena's lorcaserin will trail other obesity drugs, downgrades stock
Analyst thinks sales of Arena's lorcaserin will trail other obesity drugs, downgrades stock
Submitted by
admin
on September 16, 2009 - 9:10am
Source:
Yahoo/AP
News Tags:
downgrades
Arena Pharmaceuticals
obesity
lorcaserin
Vivus
Orexigen
Headline:
Analyst thinks sales of Arena's lorcaserin will trail other obesity drugs, downgrades stock
Do Not Allow Advertisers to Use My Personal information
